LOVE Stock Overview
Engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivated products in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Cannara Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.67 |
| 52 Week High | CA$1.04 |
| 52 Week Low | CA$0.52 |
| Beta | 1.07 |
| 11 Month Change | 8.06% |
| 3 Month Change | -12.99% |
| 1 Year Change | -25.56% |
| 33 Year Change | -50.37% |
| 5 Year Change | -52.14% |
| Change since IPO | -78.03% |
Recent News & Updates
These 4 Measures Indicate That Cannara Biotech (CVE:LOVE) Is Using Debt Extensively
Oct 29
Cannara Biotech Inc.'s (CVE:LOVE) 33% Price Boost Is Out Of Tune With Earnings
Aug 22Cannara Biotech (CVE:LOVE) Shareholders Will Want The ROCE Trajectory To Continue
Aug 21Recent updates
These 4 Measures Indicate That Cannara Biotech (CVE:LOVE) Is Using Debt Extensively
Oct 29Cannara Biotech Inc.'s (CVE:LOVE) 33% Price Boost Is Out Of Tune With Earnings
Aug 22Cannara Biotech (CVE:LOVE) Shareholders Will Want The ROCE Trajectory To Continue
Aug 21Does Cannara Biotech (CVE:LOVE) Have A Healthy Balance Sheet?
Jul 14Cannara Biotech Inc.'s (CVE:LOVE) Prospects Need A Boost To Lift Shares
May 09Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today
Feb 28Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is Lacking
Jan 24Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point
Dec 18Is Cannara Biotech (CVE:LOVE) A Risky Investment?
Jul 29Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price
Apr 10Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden
Jan 26Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear
Jan 27Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet
Dec 10Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt
Mar 16Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?
Jan 22
Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?
Dec 18Shareholder Returns
| LOVE | CA Personal Products | CA Market | |
|---|---|---|---|
| 7D | 6.3% | -3.2% | 0.7% |
| 1Y | -25.6% | 4.2% | 21.7% |
Return vs Industry: LOVE underperformed the Canadian Personal Products industry which returned 4.9% over the past year.
Return vs Market: LOVE underperformed the Canadian Market which returned 21.4% over the past year.
Price Volatility
| LOVE volatility | |
|---|---|
| LOVE Average Weekly Movement | 13.8% |
| Personal Products Industry Average Movement | 9.3% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: LOVE's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: LOVE's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Zohar Krivorot | cannara.ca |
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivated products in Canada. It also offers hemp-based CBD products. The company sells its products through wholesalers and online merchandisers.
Cannara Biotech Inc. Fundamentals Summary
| LOVE fundamental statistics | |
|---|---|
| Market cap | CA$53.11m |
| Earnings (TTM) | CA$5.32m |
| Revenue (TTM) | CA$76.69m |
11.3x
P/E Ratio0.8x
P/S RatioIs LOVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LOVE income statement (TTM) | |
|---|---|
| Revenue | CA$76.69m |
| Cost of Revenue | CA$47.81m |
| Gross Profit | CA$28.88m |
| Other Expenses | CA$23.56m |
| Earnings | CA$5.32m |
Last Reported Earnings
May 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.059 |
| Gross Margin | 37.65% |
| Net Profit Margin | 6.93% |
| Debt/Equity Ratio | 58.9% |
How did LOVE perform over the long term?
See historical performance and comparison